Wedmont Private Capital’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21M Sell
13,069
-422
-3% -$35.4K 0.03% 301
2026
Q1
$1.1M Buy
13,491
+1,769
+15% +$146K 0.04% 291
2025
Q4
$994K Sell
11,722
-823
-7% -$67.5K 0.03% 291
2025
Q3
$962K Buy
12,545
+455
+4% +$35.5K 0.04% 282
2025
Q2
$933K Buy
12,090
+2,230
+23% +$166K 0.04% 275
2025
Q1
$684K Buy
9,860
+1,512
+18% +$108K 0.04% 306
2024
Q4
$613K Buy
8,348
+398
+5% +$27.9K 0.03% 320
2024
Q3
$513K Sell
7,950
-754
-9% -$54.8K 0.03% 345
2024
Q2
$792K Buy
8,704
+515
+6% +$45.6K 0.05% 241
2024
Q1
$762K Buy
8,189
+405
+5% +$34K 0.06% 236
2023
Q4
$589K Buy
7,784
+4,514
+138% +$314K 0.05% 270
2023
Q3
$238K Buy
3,270
+319
+11% +$25.6K 0.02% 431
2023
Q2
$276K Buy
2,951
+325
+12% +$28.2K 0.03% 396
2023
Q1
$217K Buy
+2,626
New +$206K 0.03% 423
2022
Q3
Sell
-2,689
Closed -$256K 383
2022
Q2
$256K Buy
2,689
+936
+53% +$96.9K 0.06% 275
2022
Q1
$211K Buy
1,753
+10
+0.6% +$1.12K 0.05% 306
2021
Q4
$210K Buy
+1,743
New +$203K 0.06% 225

Other funds holding EW

Wedmont Private Capital's EW Position: Q2 2026 in Review

Wedmont Private Capital reduced its Edwards Lifesciences (EW) stake by 3.1% in Q2 2026, selling an estimated $35.4K and leaving 13,069 shares worth $1.21M. The position accounts for 0.03% of the portfolio, ranked #301.

Wedmont Private Capital first reported a position in EW in Q4 2021 and has held it in 17 quarters since. 372 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Wedmont Private Capital held 13,069 shares of Edwards Lifesciences worth $1.21M as of Q2 2026.
  • Wedmont Private Capital sold 422 Edwards Lifesciences shares in Q2 2026, an estimated $35.4K.
  • Edwards Lifesciences made up 0.03% of Wedmont Private Capital's portfolio in Q2 2026, its #301 holding.
  • Wedmont Private Capital first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 17 quarters since.
  • 372 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.